1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mangalam Drugs & Organics Limited

Mangalam Drugs & Organics Limited

MANGALAM.BO
Mangalam Drugs & Organics LimitedIN flagBombay Stock Exchange
28.40
INR
-0.27
- -
450.16MMarket Cap
Mangalam Drugs & Organics Limited
MANGALAM.BO
(Bombay Stock Exchange)

Recent

price

28.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
96.66
116.24
95.05
92.97
167.39
205.19
192.26
176.36
141.49
178.3
239.95
282.64
231.21
230.91
200.83
- -
146.64
Revenue per Share
1.58
0.48
-8.95
-2.31
4.66
11.15
14.07
12.57
-5.07
5.21
17.67
12.42
0.8
-5.73
4.25
- -
-28.05
Basic EPS, GAAP
-3.32
0.59
-2.13
3.93
7.7
7.45
2.07
5.42
7.8
14.92
-2.46
-1.24
7.33
-5
14.16
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
14.29
14.78
5.82
3.52
8.18
19.75
33.2
44.6
39.48
44.46
61.67
74.17
75.05
64.8
68.72
- -
10
Book Value per Share
28.4
28.88
19.93
17.62
22.28
43.14
54.12
65.08
58.06
61.79
76.34
86.42
84.48
67.79
74.08
- -
44.27
Tangible Book Value per Share
13
13
13
13
13
14
16
16
16
16
16
16
16
16
16
- -
16
Basic Weighted Avg Shares
1,274
1,532
1,253
1,225
2,206
2,950
3,043
2,792
2,239
2,822
3,798
4,474
3,660
3,655
3,176
2,321
2,321
Sales/Revenue/Turnover
7.74
7.38
-5.41
4.76
7.38
11.33
13.7
14.43
1.18
5.5
11.7
8.66
3.99
0.29
5.84
-14.27
-14.04
Operating Margin (%)
33
37
39
40
42
44
50
66
75
82
92
102
110
75
166
182
182
Depreciation Expense
21
6
-118
-30
61
160
223
199
-80
83
280
197
13
-91
67
-444
-444
Net Income, GAAP
30.48
44.31
- -
- -
- -
33.24
28.56
32.23
- -
- -
29.22
29.12
42.63
- -
- -
- -
- -
Effective Tax Rate (%)
1.64
0.41
-9.42
-2.48
2.78
5.43
7.32
7.13
-3.59
2.92
7.36
4.39
0.35
-2.48
2.12
-19.13
-19.13
Profit Margin (%)
67
74
143
100
166
269
180
230
142
97
248
549
412
119
74
-409
-409
Working Capital
192
220
439
402
394
169
169
111
105
50
101
303
255
185
117
86
86
LT Debt
374
381
263
232
294
621
857
1,038
957
1,039
1,308
1,506
1,520
1,358
1,490
1,031
1,031
Total Equity
8.23
7.02
- -
- -
- -
20.17
22.1
17.14
- -
- -
17.65
12.45
3.48
- -
- -
- -
- -
Return on Invested Capital (%)
3.38
0.89
- -
- -
- -
23.81
26.14
19.93
- -
- -
22.4
13.29
3.1
- -
- -
- -
- -
Return on Capital (%)
11.74
3.31
-86.95
-49.4
79.73
81.87
55.04
32.3
-12.07
12.42
33.3
18.28
1.08
-8.2
6.36
-71.33
-71.33
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
819
- -
969
LT Borrowings
113
- -
75
LT Finance Leases
17
- -
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
- -
16
Market Capitalization
1,120
430
439

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,528
- -
1,557
Cash, Cash Equivalents & STI
97
- -
39
Accounts Receivable, Net
170
- -
403
Inventories
1,169
- -
1,028
Total Current Liabilities
1,687
- -
1,966
Payables & Accruals
- -
- -
- -
ST Debt
819
- -
969
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.01%
-3.14%
-30.82%
Free Cash Flow
-131.58%
-285.47%
-134.48%
Net Income, GAAP
-194.83%
-374.46%
-760.65%
Sales/Revenue/Turnover
-0.48%
-8.11%
-26.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
870
814
970
- -
3,655
2025
765
798
886
728
3,176
2026
572
493
584
673
2,321

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.02
- -
0.31
- -
-5.73
2025
1.7
1.7
0.81
0.04
4.25
2026
-8.72
-4.64
-6.21
-8.48
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Aurobindo Pharma Limited (AUROPHARMA.BO)
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (002864.SZ)
Bal Pharma Limited (BALPHARMA.NS)
Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
Celltrion Pharm, Inc. (068760.KQ)
Elanco Animal Health Incorporated (ELAN)
Business
Mangalam Drugs & Organics Limited manufactures and markets active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and drug intermediates primarily focused on anti-malarial and anti-biotic segments; its core product portfolio includes Chloroquine Phosphate, Hydroxychloroquine Sulphate, Primaquine Phosphate, and Pamaquine Naphthoate, along with other APIs such as Metformin Hydrochloride and Doxycycline Hyclate. The company offers contract research and manufacturing services (CRAMS) for pharmaceutical intermediates and supports bulk drug production for domestic and international markets. Founded in 1994 and headquartered in Mumbai, India, Mangalam Drugs & Organics operates manufacturing facilities in Maharashtra, India, serving pharmaceutical companies in India, the United States, Europe, and Africa.